Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase 2 trial to compare TP-06 2.0% ophthalmic solution with a placebo vehicle in adults who have persistent corneal epithelial defects PCED that have not healed after at least 10 days of standard treatment. This trial aims to evaluate the safety and effectiveness of TP-06 in promoting corneal healing, improving visual acuity, and assessing changes in corneal thickness. Participants will be randomly assigned to receive either TP-06 2.0% or the vehicle four times daily for 8 weeks, alongside required background therapy. After the treatment phase, there will be a 2-week follow-up period to monitor healing and safety. The study is double-masked and involves multiple centers. During the study, participants will undergo assessments including evaluation of corneal healing through fluorescein staining, measurement of lesion size with imaging, and tests of visual acuity. Researchers will monitor the timing and extent of corneal healing and any safety concerns. The total participation time includes 8 weeks of treatment plus 2 weeks of follow-up.
Actively Recruiting
Researchers are evaluating the safety of the IC-8 Apthera intraocular lens IOL after treatment for posterior capsular opacification PCO, a common complication following IC-8 Apthera IOL implantation. This prospective, multi-center, non-randomized study focuses on patients who have already received the IC-8 Apthera IOL and now require NdYAG laser capsulotomy for PCO. The study aims to verify post-market safety following training in a standardized laser treatment technique. Participants previously implanted with the IC-8 Apthera IOL and experiencing PCO will be treated with NdYAG laser capsulotomy using a sponsor-recommended method. There is one study group, and subjects will be followed for 24 months after their IC-8 Apthera IOL implantation. The study includes about six visits over this two-year period to monitor safety and treatment outcomes. During the study, participants will undergo assessments of laser treatment outcomes, any complications, and IOL-related evaluations. Researchers will track additional laser treatments, secondary surgical interventions, ocular and serious adverse events, and subjective visual disturbances using specific questionnaires. The study lasts for two years post-implantation, with regular visits to ensure thorough monitoring of participant eye health and treatment effects.